Amit Maity
( out of 40 reviews )

Amit Maity, MD, PhD, FASTRO

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
1950 Circle of Hope
Salt Lake City , UT 84112
Get Directions

Amit Maity is Professor and Chair of the Department of Radiation Oncology at the University of Utah School of Medicine where he holds the Huntsman Cancer Institute Endowed Chair in Cancer Research. In this role, he leads the efforts of faculty and staff in the department located in the Huntsman Cancer Hospital to provide clinical care to patients requiring radiation treatment and also promotes the educational and research missions of the department. He received an MD at Boston University School of Medicine, then completed a residency in internal medicine at Mount Sinai Hospital in New York, a residency in radiation oncology at the Hospital of the University of Pennsylvania in Philadelphia, and a PhD in pathology at the University of Pennsylvania.

Specialties

Board Certification

American Board of Internal Medicine (Internal Medicine)
American Board of Radiology (Radiation Oncology)

Patient Rating

Patients describe Dr. Maity as caring, kind, and personable, with genuine concern for recovery and ongoing health. He is praised for clear, thorough explanations of procedures, treatment options, and follow-up care, using plain language and answering questions fully. Reviewers also note his professionalism, expertise, respect for patient decisions, and willingness to coordinate and accommodate care.

Generated via Patient Reviews

4.9 /5
( out of 40 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.

Amit Maity is Professor and Chair of the Department of Radiation Oncology at the University of Utah School of Medicine where he holds the Huntsman Cancer Institute Endowed Chair in Cancer Research. In this role, he leads the efforts of faculty and staff in the department located in the Huntsman Cancer Hospital to provide clinical care to patients requiring radiation treatment and also promotes the educational and research missions of the department. He received an MD at Boston University School of Medicine, then completed a residency in internal medicine at Mount Sinai Hospital in New York, a residency in radiation oncology at the Hospital of the University of Pennsylvania in Philadelphia, and a PhD in pathology at the University of Pennsylvania.

Board Certification and Academic Information

Academic Departments Radiation Oncology -Professor
Board Certification
American Board of Internal Medicine (Internal Medicine)
American Board of Radiology (Radiation Oncology)

Education history

Other Training Leadership Development Program - Harvard School of Public Health
Postdoctoral Training Johns Hopkins University School of Medicine Postdoctoral Researcher
Doctoral Training Pathology - University of Pennsylvania Ph.D.
Postdoctoral Training University of Pennsylvania School of Medicine Postdoctoral Training
Fellowship Radiation Oncology - Hospital of the University of Pennsylvania Fellow
Residency Radiation Oncology - Hospital of the University of Pennsylvania Resident
Residency Internal Medicine - Mount Sinai Hospital Resident
Internship Internal Medicine - Mount Sinai Hospital Intern
Professional Medical Medicine - Boston University School of Medicine M.D.
Undergraduate Mathematics - Boston University B.A.

Selected Publications

Journal Article

  1. Howell JN, Mark B, Wada DA, Bowling M, Wei M, Lloyd SL, Gaffney DK, Maity A, LaRiviere MJ, Rule WG, Grant JD, Deshmukh V, Newman M, Date A, Hashibe M, Tao R (2024). Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes. Cancer Med, 14(5), e70577.
  2. Kostopoulos N, Costabile F, Krimitza E, Beghi S, Goia D, Perales-Linares R, Thyfronitis G, LaRiviere MJ, Chong EA, Schuster SJ, Maity A, Koumenis C, Plastaras JP, Facciabene A (2024). Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration. Blood Adv, 8(24), 6308-6320.
  3. Verginadis II, Velalopoulou A, Kim MM, Kim K, Paraskevaidis I, Bell B, Oliaei Motlagh SA, Karaj A, Banerjee E, Finesso G, Assenmacher CA, Radaelli E, Lu J, Lin Y, Putt ME, Diffenderfer ES, Guha C, Qin L, Metz JM, Maity A, Cengel KA, Koumenis C, Busch TM (2024). FLASH proton reirradiation, with or without hypofractionation, mitigates chronic toxicity in the normal murine intestine, skin, and bone. bioRxiv.
  4. Baron JA, Wright CM, Dreyfuss AD, Chong EA, Svoboda J, LaRiviere MJ, Jones JA, Maity A, Plastaras JP, Paydar I, Maxwell R (2024). Radiotherapy dose response in bulky relapsed/refractory large B-cell lymphoma. Pract Radiat Oncol.
  5. Perales-Linares R, Leli NM, Mohei H, Beghi S, Rivera OD, Kostopoulos N, Giglio A, George SS, Uribe-Herranz M, Costabile F, Pierini S, Pustylnikov S, Skoufos G, Barash Y, Hatzigeorgiou AG, Koumenis C, Maity A, Lotze MT, Facciabene A (2023). Parkin deficiency suppresses antigen presentation to promote tumor immune evasion and immunotherapy resistance. Cancer Res.
  6. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 356-363.
  7. Yegya-Raman N, Wright CM, LaRiviere MJ, Baron JA, Lee DY, Landsburg DJ, Svoboda J, Nasta SD, Gerson JN, Barta SK, Chong EA, Schuster SJ, Maity A, Facciabene A, Paydar I, Plastaras JP (2023). Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy. Clin Transl Radiat Oncol, 39, 100587.
  8. Zou W, Kim H, Diffenderfer ES, Carlson DJ, Koch CJ, Xiao Y, Teo BK, Kim MM, Metz JM, Fan Y, Maity A, Koumenis C, Busch TM, Wiersma R, Cengel KA, Dong L (2022). A phenomenological model of proton FLASH oxygen depletion effects depending on tissue vasculature and oxygen supply. Front Oncol, 12, 1004121.
  9. Baron JA, Wright CM, Maxwell R, Kim MM, Giap F, Vega RBM, Hoppe BS, LaRiviere MJ, Maity A, Plastaras JP, Paydar I (2022). Proton Radiation Therapy After Chemotherapy in the Management of Aggressive Mediastinal Non-Hodgkin Lymphomas: A Particle Therapy Cooperative Group Lymphoma Subcommittee Collaboration. Adv Radiat Oncol, 8(1), 101090.
  10. Anstadt EJ, Chu B, Yegya-Raman N, Han X, Doucette A, Poirier K, Mohiuddin JJ, Maity A, Facciabene A, Amaravadi RK, Karakousis GC, Cohen JV, Mitchell TC, Schuchter LM, Lukens JN (2021). Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist, 27(9), 799-808.
  11. Freyer CW, Babushok DV, Frey NV, Gill SI, Loren AW, Luger SM, Maity A, Martin ME, Plastaras JP, Porter DL, Hexner EO (2022). Low-Dose Total Body Irradiation Added to Fludarabine and Busulfan Reduced-Intensity Conditioning Reduces Graft Failure in Patients with Myelofibrosis. Transplant Cell Ther, 28(9), 590-596.
  12. Wright CM, Dreyfuss AD, Baron JA, Maxwell R, Mendes A, Barsky AR, Doucette A, Svoboda J, Chong EA, Jones JA, Maity A, Plastaras JP, Paydar I (2022). Radiation Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: What Is the Right Regimen for Palliation? Adv Radiat Oncol, 7(6), 101016.
  13. Zhong L, Yao L, Holdreith N, Yu W, Gui T, Miao Z, Elkaim Y, Li M, Gong Y, Pacifici M, Maity A, Busch TM, Joeng KS, Cengel K, Seale P, Tong W, Qin L (2022). Transient expansion and myofibroblast conversion of adipogenic lineage precursors mediate bone marrow repair after radiation. JCI Insight, 7(7).
  14. Demissei BG, Freedman G, Feigenberg SJ, Plastaras JP, Maity A, Smith AM, McDonald C, Sheline K, Simone CB 2nd, Lin LL, Carver JR, Liu P, Zhang L, Bekelman JE, Ky B (2018). Early Changes in Cardiovascular Biomarkers with Contemporary Thoracic Radiation Therapy for Breast Cancer, Lung Cancer, and Lymphoma. Int J Radiat Oncol Biol Phys, 103(4), 851-860.

Review

  1. Verginadis II, Citrin DE, Ky B, Feigenberg SJ, Georgakilas AG, Hill-Kayser CE, Koumenis C, Maity A, Bradley JD, Lin A (2025). Radiotherapy toxicities: mechanisms, management, and future directions. [Review]. Lancet, 405(10475), 338-352.
  2. Zou W, Zhang R, Schler E, Taylor PA, Mascia AE, Diffenderfer ES, Zhao T, Ayan AS, Sharma M, Yu SJ, Lu W, Bosch WR, Tsien C, Surucu M, Pollard-Larkin JM, Schuemann J, Moros EG, Bazalova-Carter M, Gladstone DJ, Li H, Simone CB 2nd, Petersson K, Kry SF, Maity A, Loo BW Jr, Dong L, Maxim PG, Xiao Y, Buchsbaum JC (2023). Framework for Quality Assurance of Ultrahigh Dose Rate Clinical Trials Investigating FLASH Effects and Current Technology Gaps. [Review]. Int J Radiat Oncol Biol Phys, 116(5), 1202-1217.
  3. Graves EE, Maity A, Le QT (2010). The tumor microenvironment in non-small-cell lung cancer. [Review]. Semin Radiat Oncol, 20(3), 156-63.

Conference Proceedings

  1. Zhu Y, Alexander DA, Miao T, Maity A, Plastaras JP, Paydar I, LaRiviere M, Pogue BW, Zhu TC (2023). Evaluation of the cumulative Cherenkov converted dose on TSET patients with multiple Cherenkov cameras. Proc SPIE Int Soc Opt Eng, United States, 12359.

News & Podcasts

Huntsman Cancer Institute News